Cirrhosis is advanced, long-term scarring of the liver. After years of injury from alcohol, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly fatty liver disease), hepatitis B or C or another cause, scar tissue and nodules replace healthy liver tissue. The liver stiffens, pressure rises in the portal vein (portal hypertension) and the liver slowly loses its ability to make proteins and clear toxins. About 1 in 400 adults in the United States has cirrhosis, and many do not know it.
Cirrhosis has two main stages. In compensated cirrhosis, people often feel well and the disease is found on blood tests, an ultrasound or a liver stiffness scan. In decompensated cirrhosis, complications appear: fluid in the belly (ascites), bleeding from swollen veins (varices), confusion (hepatic encephalopathy) or yellow skin (jaundice). Median survival is more than 15 years in the compensated stage and about 2 years after decompensation. Early diagnosis and treating the cause matter.
Key takeaways
- Cirrhosis is the end stage of liver fibrosis (F4 on the F0 to F4 scale). The most common US causes are alcohol, MASLD and chronic hepatitis C or B.
- Early cirrhosis is often silent. Low platelets, low albumin, high bilirubin, a high INR and an AST higher than ALT are clues on routine blood tests.
- Doctors stage severity with the Child-Pugh class (A, B, C) and the MELD 3.0 score, and estimate scarring with FIB-4 and elastography.
- Removing the cause (stopping alcohol, curing hepatitis C, controlling hepatitis B, losing weight) can stabilize cirrhosis and sometimes lead to "recompensation."
- Everyone with cirrhosis needs liver cancer screening with ultrasound and AFP about every 6 months.
What is cirrhosis of the liver?
Each time the liver repairs an injury, it leaves a little scar tissue (fibrosis). When injury continues for years, a 2021 Lancet review explains, fibrous tissue and regenerative nodules replace healthy liver tissue, leading to portal hypertension and, eventually, liver failure.
Pathologists score fibrosis from F0 (no fibrosis) to F4 (cirrhosis). F2 is moderate fibrosis, F3 is advanced (bridging) fibrosis and F4 is cirrhosis. Some new medicines are approved only for F2 to F3, before cirrhosis. To see how blood markers estimate where you are on this scale, read our guide to liver fibrosis tests such as GGT and FIB-4.
Fatty liver (steatosis) is common and often reversible; cirrhosis can follow many years of inflammation. If you have a fatty liver, our page on fatty liver disease (MASLD) explains how to keep it from progressing.
How common is cirrhosis?
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that about 1 in 400 US adults has cirrhosis. A US population study based on national survey data estimated a prevalence of 0.27%, about 633,000 adults, and 69% of them reported that they were unaware of having liver disease. Worldwide, cirrhosis was associated with 2.4% of all deaths in 2019, and deaths from MASLD-related cirrhosis are rising while deaths from viral causes decline, according to a 2023 review in Nature Reviews Gastroenterology and Hepatology.
Causes and risk factors
According to the NIDDK, the most common causes of cirrhosis in the United States are:
- Alcohol-related liver disease. Long-term heavy drinking is a leading cause; see our summary of how much alcohol is too much.
- Metabolic dysfunction-associated steatotic liver disease (MASLD), linked to overweight, obesity, type 2 diabetes and metabolic syndrome. Its inflammatory form is called MASH.
- Chronic hepatitis C and chronic hepatitis B infection.
Less common causes include autoimmune hepatitis, bile duct diseases such as primary biliary cholangitis and primary sclerosing cholangitis, inherited diseases (Wilson disease, hemochromatosis, alpha-1 antitrypsin deficiency), long-term use of certain medicines or high doses of vitamin A, and chronic heart failure with liver congestion. Some people have more than one cause, and in some no cause is found.
People more likely to develop cirrhosis include those with a history of heavy alcohol use, overweight or obesity, type 2 diabetes, men and adults aged 40 or older (NIDDK). In the US survey study, more than half of cases were attributed to viral hepatitis, diabetes and alcohol, all preventable or treatable.
Cirrhosis symptoms and early signs
In the earliest stage, there may be no symptoms at all. When early symptoms appear, the NIDDK lists:
- Fatigue or weakness, and loss of muscle with cramps.
- Itchy skin.
- Poor appetite, nausea, unintended weight loss.
- Mild discomfort in the upper right part of the belly.
- Sexual problems.
Cleveland Clinic adds spider-like blood vessels and red palms. Later, liver cirrhosis symptoms become visible:
- Swelling of the belly from fluid (ascites) and of the legs, ankles or feet (edema).
- Yellow skin and eyes (jaundice), dark urine and severe itching.
- Easy bruising and bleeding.
- Confusion, memory problems, personality changes or sleep problems (hepatic encephalopathy).
- Vomiting blood or black stools from bleeding varices.
A new yellow tint, a growing belly or unexplained weight loss in someone with cirrhosis can also be a sign of liver cancer; our article on liver cancer symptoms lists the warning signs.
Stages of cirrhosis
There is no single "stage 1 to 4" system used by every doctor. Three scales are used in practice.
Fibrosis stage (F0 to F4)
It describes how much scar the liver holds, from a biopsy or estimated by elastography and blood scores. F4 is cirrhosis; F3 is advanced fibrosis not yet cirrhosis.
Compensated, decompensated and further decompensated cirrhosis
This is the most useful clinical staging. A 2024 American Gastroenterological Association (AGA) expert review gives median survival of more than 15 years for compensated cirrhosis, 2 years for decompensated cirrhosis and 9 months for further decompensated cirrhosis.
Researchers split these states further: compensated cirrhosis progresses from mild portal hypertension to clinically significant portal hypertension (CSPH, a gradient of 10 mm Hg or more), then varices; a late stage (refractory ascites, sepsis, kidney failure, acute-on-chronic liver failure) predicts very short survival.
Child-Pugh class and MELD score
The Child-Pugh score adds points for bilirubin, albumin, INR, ascites and encephalopathy: class A is 5 to 6 points, class B 7 to 9 and class C 10 to 15. The MELD 3.0 score uses only lab values plus sex (bilirubin, sodium, creatinine, albumin, INR) and predicts 90-day survival. It ranks people waiting for a liver transplant in the United States, and a MELD 3.0 of 15 or higher should prompt referral for transplant evaluation, according to the Merck Manual.
How cirrhosis is diagnosed
Diagnosis combines your history, an exam, blood tests, imaging and, only when results are unclear, a liver biopsy (NIDDK).
- Liver tests: ALT, AST, alkaline phosphatase, bilirubin and albumin. Our guide to liver function tests explains each one.
- Complete blood count, looking for low platelets, anemia or infection.
- Clotting: prothrombin time and INR, explained in our coagulation panel guide.
- Cause-finding tests: hepatitis B surface antigen (see our page on a positive HBsAg result), the hepatitis C antibody test and autoimmune antibodies.
- Imaging: ultrasound, CT or MRI can show a nodular liver, a big spleen or ascites.
- Elastography: transient elastography (FibroScan) or magnetic resonance elastography (MRE) measures liver stiffness in kilopascals (kPa). A 2024 systematic review for the AASLD found them most accurate for cirrhosis (F4), with MRE the most accurate.
FIB-4 and elastography: the two-step approach
FIB-4 is a free score from age, AST, ALT and platelets; guidelines use it first, then liver stiffness when it is not low. In a 2025 study of 12,950 people with MASLD, FIB-4 below 1.3 (below 2.0 at age 65 or older) defined low risk and above 2.67 high risk. After adding elastography, the 5-year risk of a liver complication was 0.5%, 1.0% and 10.8% in the low, intermediate and high-risk groups.
Liver blood tests in cirrhosis: reference values
Usual reference ranges and their meaning in cirrhosis. Ranges vary between laboratories; compare with your report.
| Test | Usual range (US units) | Usual range (SI units) | What it suggests in cirrhosis |
|---|---|---|---|
| Albumin | 3.4 to 5.4 g/dL | 34 to 54 g/L | Low = reduced production; below 2.8 g/dL scores 3 Child-Pugh points |
| Total bilirubin | 0.1 to 1.2 mg/dL | 1.7 to 20.5 µmol/L | Normal early; above 3 mg/dL (51 µmol/L) scores 3 points |
| INR (no blood thinner) | 0.8 to 1.1 | 0.8 to 1.1 (no unit) | Fewer clotting factors; above 2.3 scores 3 points |
| Platelets | 150,000 to 400,000 per µL | 150 to 400 × 10⁹/L | Low count can signal portal hypertension |
| ALT | 4 to 36 U/L | 0.07 to 0.60 µkat/L | Often only mildly raised, or normal |
| AST | 8 to 33 U/L | 0.13 to 0.55 µkat/L | AST/ALT above 2 with high GGT suggests alcohol |
| Sodium | 135 to 145 mEq/L | 135 to 145 mmol/L | Low in advanced cirrhosis (extra body water); part of MELD 3.0 |
| FIB-4 score | Below 1.3 (below 2.0 at 65+) | Same (no unit) | 1.3 to 2.67: needs elastography; above 2.67: high risk of advanced fibrosis |
| Liver stiffness (transient elastography) | Below 10 kPa | Below 10 kPa | Above 15 kPa: advanced disease likely; 25 kPa or more: CSPH |
| Child-Pugh class | A: 5-6, B: 7-9, C: 10-15 points | Same | 1-year survival about 90-96% (A), 73-78% (B), 41-51% (C) |
Sources: MedlinePlus (ranges), Merck Manual (Child-Pugh), Baveno VII (stiffness, platelets), VCTE-Prognosis 2025 (FIB-4). Bilirubin: 1 mg/dL = 17.1 µmol/L.
How to read your liver test results
No single number makes the diagnosis. Doctors look at patterns:
- Liver enzymes can be normal. ALT and AST are often only modestly raised in cirrhosis (Merck Manual). A normal ALT (SGPT) result does not rule out scarring.
- The AST to ALT ratio helps. An AST level higher than ALT is common in advanced fibrosis and in alcohol-related disease; our page on the AST/ALT (De Ritis) ratio explains the cut-offs.
- "Synthetic" tests show how well the liver works. Low albumin, a high INR and a rising total bilirubin point to reduced liver function and usually appear later.
- Low platelets are an early clue. A falling platelet count often reflects a large spleen from portal hypertension. Baveno VII states that liver stiffness of 15 kPa or less with platelets of 150 × 10⁹/L or more rules out clinically significant portal hypertension.
- Low sodium matters in advanced disease. A low sodium blood test result with ascites signals a more serious stage.
Cirrhosis treatment and follow-up
Treat the cause
The NIDDK lists cause-specific treatment as the first step: stopping alcohol completely, weight loss for MASLD, antiviral medicines for hepatitis C (curing more than 95% of people in 8 to 12 weeks) and for hepatitis B, and immune-suppressing medicines for autoimmune hepatitis. Baveno VII defines removal of the cause as a cure of hepatitis C, sustained suppression of hepatitis B and long-term abstinence from alcohol.
Prevent and treat complications
- Portal hypertension: Baveno VII recommends considering a non-selective beta-blocker (propranolol, nadolol or carvedilol) to prevent decompensation in people with CSPH. (carvedilol: ChEMBL CHEMBL723).
- Ascites and edema: diuretics, limiting salt and draining fluid when needed (NIDDK). The 2024 AGA update advises giving intravenous albumin when more than 5 liters are removed.
- Variceal bleeding: an emergency. Vasoactive drugs (octreotide is preferred) should start as soon as bleeding is suspected, before endoscopy, and continue 2 to 5 days (AGA).
- Hepatic encephalopathy: medicines that lower toxins from the gut, such as lactulose and rifaximin.
- Hepatorenal syndrome: terlipressin with albumin is the treatment of choice for this kidney failure (AGA).
Liver cancer screening
Cirrhosis is the main risk factor for hepatocellular carcinoma. The AASLD 2023 guidance recommends ultrasound plus alpha-fetoprotein about every 6 months. Adding AFP raises early cancer detection from 53% to 63%. Our guide to the AFP blood test explains how to read the result.
Liver transplant
When cirrhosis leads to liver failure, a transplant is the only cure (NIDDK). MELD 3.0, which added albumin and sex to the older formula, ranks candidates more fairly, especially women.
Living with cirrhosis and prevention
The NIDDK advises people with cirrhosis to:
- Avoid alcohol and illegal drugs completely.
- Check with a doctor before any medicine, including NSAIDs, acetaminophen, sleep aids and supplements.
- Limit salt to help control fluid build-up.
- Avoid raw or undercooked shellfish, fish and meat.
- Get vaccinated against hepatitis A and B, flu, pneumococcal pneumonia and shingles.
When to see a doctor
See your doctor if you have liver risk factors and notice tiredness, itching, swelling or yellow eyes, or if a blood test shows low platelets, low albumin, high bilirubin, an AST higher than ALT or a FIB-4 above 1.3.
Call 911 or go to the emergency room right away if someone with cirrhosis vomits blood or material that looks like coffee grounds, passes black or bloody stools, becomes confused or very sleepy, has a fever with belly pain, or has a sudden drop in urine output. Variceal bleeding, infection of ascites fluid and hepatic encephalopathy are emergencies.
Latest scientific advances in cirrhosis
New names: MASLD, MASH and MetALD (2023)
In 2023, three international liver societies replaced "NAFLD" and "NASH" with metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). A new category, MetALD, covers people with MASLD who drink more (140 to 350 g of alcohol per week for women and 210 to 420 g for men). Older reports use the old names for the same diseases.
First MASH drugs: approved before cirrhosis, tested in cirrhosis (2024-2026)
On March 14, 2024, the FDA granted accelerated approval to resmetirom (Rezdiffra, ChEMBL CHEMBL3261331), a thyroid hormone receptor beta agonist, for adults with noncirrhotic MASH and moderate to advanced fibrosis. In the MAESTRO-NASH trial (NCT03900429, 966 patients with F1B to F3), MASH resolved in 25.9% to 29.9% of treated patients versus 9.7% with placebo. The FDA states that it should be avoided in decompensated cirrhosis. It is not approved for cirrhosis: the MAESTRO-NASH-OUTCOMES trial (NCT05500222, 845 participants with compensated Child-Pugh A MASH cirrhosis) is testing whether it prevents decompensation, transplant or death, with primary completion expected in December 2026.
Semaglutide 2.4 mg (Wegovy, ChEMBL CHEMBL2108724) received accelerated FDA approval in August 2025 for MASH with F2 to F3 fibrosis, based on the ESSENCE trial (NCT04822181): at 72 weeks, MASH resolved in 62.9% versus 34.3% with placebo, and fibrosis improved in 36.8% versus 22.4%. The November 2025 AASLD update stresses that it is not approved for MASH cirrhosis (for example, stiffness above 20 kPa).
Efruxifermin in compensated MASH cirrhosis (2025)
The SYMMETRY phase 2b trial (NCT05039450) tested efruxifermin, an FGF21 analog, in 181 people with biopsy-proven compensated MASH cirrhosis. It missed its primary goal at 36 weeks (fibrosis improved in 19% with 50 mg versus 13% with placebo). At 96 weeks, fibrosis improved in 29% with 50 mg versus 11% with placebo. Phase 3 trials are needed.
Noninvasive tests replace many biopsies (2022-2025)
The Baveno VII consensus and the AASLD 2024 guideline reviews established liver stiffness as the main tool to detect advanced disease and portal hypertension. A systematic review supporting the AASLD guideline found that portal hypertension is highly unlikely at a stiffness of 15 kPa or less and likely at 25 kPa or more, while blood scores such as FIB-4 and APRI were less accurate for this purpose. For patients: fewer biopsies and earlier beta-blockers.
Recompensation after hepatitis C cure (2025)
Baveno VII introduced "recompensation": cure or control of the cause, resolution of ascites and encephalopathy without medicines and no recurrent variceal bleeding for at least 12 months, and stable improvement of albumin, INR and bilirubin. In a 2025 European study of 361 people with decompensated cirrhosis cured of hepatitis C, 36.6% achieved recompensation, and liver-related deaths fell (4.2 versus 8.8 per 100 patient-years). Liver cancer risk did not fall, so screening every 6 months must continue.
Which tests can help?
Tests to discuss with your doctor:
- A liver panel (ALT, AST, alkaline phosphatase, GGT, bilirubin, albumin) and a complete blood count with platelets.
- PT/INR, sodium and creatinine, which are needed for the Child-Pugh and MELD 3.0 scores.
- The FIB-4 score from your age, AST, ALT and platelets, then elastography if FIB-4 is 1.3 or higher.
- Hepatitis B surface antigen and hepatitis C antibody, plus other cause-finding tests if needed.
- Alpha-fetoprotein with a liver ultrasound every 6 months once cirrhosis is diagnosed.
Trends matter: a falling platelet count or albumin often says more than one value.
Glossary
- Ascites: fluid that collects in the belly because of portal hypertension and low albumin.
- Child-Pugh score: a 5 to 15 point score (classes A, B, C) based on bilirubin, albumin, INR, ascites and encephalopathy.
- CSPH: clinically significant portal hypertension, a portal pressure gradient of 10 mm Hg or more.
- FIB-4: a fibrosis score calculated from age, AST, ALT and platelet count.
- MASLD / MASH: metabolic dysfunction-associated steatotic liver disease and its inflammatory form, steatohepatitis.
- MELD 3.0: a score from bilirubin, sodium, creatinine, albumin, INR and sex that predicts 90-day survival.
- Varices: swollen veins in the esophagus or stomach that can bleed.
Frequently asked questions
What is decompensated cirrhosis of the liver?
Decompensated cirrhosis means the scarred liver can no longer cope and a major complication has appeared: ascites, bleeding from varices, hepatic encephalopathy or jaundice. It marks a turning point: the AGA gives a median survival of about 2 years after decompensation, compared with more than 15 years in compensated cirrhosis. Treating the cause and early transplant evaluation improve this outlook.
What are the newest treatments for cirrhosis?
Resmetirom (2024) and semaglutide (2025) are FDA-approved for MASH with F2 to F3 fibrosis, before cirrhosis. In cirrhosis itself, resmetirom is being tested in the MAESTRO-NASH-OUTCOMES trial and efruxifermin showed fibrosis improvement at 96 weeks in a phase 2b trial. The biggest gains still come from treating the cause and from beta-blockers for portal hypertension.
How to help someone with liver failure?
Help them stay completely away from alcohol, take medicines exactly as prescribed and check every new medicine or supplement with their doctor. Support a low-salt diet, food safety and vaccinations, and go with them to appointments and 6-month liver cancer screening. Call 911 for vomiting blood, black stools, new confusion or fever with belly pain.
How long can you live with cirrhosis of the liver stage 3?
It depends on what "stage 3" means. If it means fibrosis stage F3, it is not yet cirrhosis, and treating the cause can stop or reverse scarring. If it refers to decompensated cirrhosis, for example with ascites, median survival is around 2 years according to the AGA, but outcomes vary; Child-Pugh and MELD 3.0 give a personal estimate.
Can cirrhosis be reversed?
Sometimes, partly. Cirrhosis was long considered irreversible, but the Merck Manual notes evidence that it can be reversed, and Baveno VII describes "recompensation" when the cause is removed. Early cirrhosis has the best chance of regressing.
What are the early signs of cirrhosis?
Often there are none. When present, early signs include fatigue, itching, poor appetite, nausea, weight loss, mild pain under the right ribs, muscle cramps, spider-like blood vessels and red palms. Low platelets or an AST higher than ALT on a routine blood test may be the first clue.
Sources
- Ginès P, Krag A, Abraldes JG et al. — Liver cirrhosis — Lancet, 2021 — doi.org
- Huang DQ, Terrault NA, Tacke F et al. — Global epidemiology of cirrhosis: aetiology, trends and predictions — Nat Rev Gastroenterol Hepatol, 2023 — doi.org
- Scaglione S, Kliethermes S, Cao G et al. — The epidemiology of cirrhosis in the United States: a population-based study — J Clin Gastroenterol, 2015 — doi.org
- Garcia-Tsao G, Abraldes JG, Rich NE, Wong VW — AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: expert review — Gastroenterology, 2024 — doi.org
- D'Amico G, Morabito A, D'Amico M et al. — New concepts on the clinical course and stratification of compensated and decompensated cirrhosis — Hepatol Int, 2018 — doi.org
- de Franchis R, Bosch J, Garcia-Tsao G et al. — Baveno VII: renewing consensus in portal hypertension — J Hepatol, 2022 — doi.org
- Duarte-Rojo A, Taouli B, Leung DH et al. — Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline — Hepatology, 2025 — doi.org
- Rockey DC, Alsawas M, Duarte-Rojo A et al. — Noninvasive liver disease assessment to identify portal hypertension: systematic and narrative reviews supporting the AASLD Practice Guideline — Hepatology, 2025 — doi.org
- Yip TC, Lee HW, Lin H et al. — Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease — J Hepatol, 2025 — doi.org
- Kim WR, Mannalithara A, Heimbach JK et al. — MELD 3.0: the model for end-stage liver disease updated for the modern era — Gastroenterology, 2021 — doi.org
- Singal AG, Llovet JM, Yarchoan M et al. — AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma — Hepatology, 2023 — doi.org
- Rinella ME, Lazarus JV, Ratziu V et al. — A multisociety Delphi consensus statement on new fatty liver disease nomenclature — Hepatology, 2023 — doi.org
- Harrison SA, Bedossa P, Guy CD et al. — A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis — N Engl J Med, 2024 — doi.org
- Sanyal AJ, Newsome PN, Kliers I et al. — Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis — N Engl J Med, 2025 — doi.org
- Bansal MB, Patton H, Morgan TR et al. — Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance — Hepatology, 2025 — doi.org
- Noureddin M, Rinella ME, Chalasani NP et al. — Efruxifermin in compensated liver cirrhosis caused by MASH — N Engl J Med, 2025 — doi.org
- Semmler G, Lens S, Hidalgo Á et al. — Incidence and clinical significance of recompensation after HCV cure — Clin Gastroenterol Hepatol, 2025 — doi.org
- ClinicalTrials.gov — MAESTRO-NASH-OUTCOMES: resmetirom in well-compensated NASH cirrhosis (NCT05500222) — clinicaltrials.gov
- US Food and Drug Administration — FDA approves first treatment for patients with liver scarring due to fatty liver disease — 2024 — fda.gov
- NIDDK — Cirrhosis: definition and facts, symptoms, diagnosis — National Institutes of Health — niddk.nih.gov
- NIDDK — Treatment for cirrhosis — National Institutes of Health — niddk.nih.gov
- Merck Manual Professional Version — Cirrhosis — merckmanuals.com
- MedlinePlus — Albumin, bilirubin, PT/INR, platelet, ALT, AST and sodium blood tests — National Library of Medicine — medlineplus.gov
- Cleveland Clinic — Cirrhosis of the liver — 2025 — my.clevelandclinic.org
- EMBL-EBI — ChEMBL: resmetirom (CHEMBL3261331), semaglutide (CHEMBL2108724), carvedilol (CHEMBL723) — ChEMBL — ebi.ac.uk
Further reading
- Hepatitis blood test: what the results mean
- GGT test: liver enzyme results explained
- Low albumin: causes, symptoms and when to worry
- Bile acids: the liver marker panels skip
- Liver cancer prognosis: what shapes survival
- Fatty liver blood test: can it catch MASLD?
- Hemochromatosis treatment: phlebotomy and beyond
Understand your lab results with AI DiagMe
A low platelet count, a borderline albumin, a high bilirubin or a puzzling AST/ALT ratio can be hard to interpret alone. AI DiagMe reads your blood test report in minutes, explains each value in plain language, highlights patterns worth discussing and suggests questions for your doctor. Upload your lab results to AI DiagMe for a clear, personal report.



